ArticleJTO clinical and research reports2023

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.

Arkadiusz Z Dudek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.